Degarelix vs Triptorelin
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, Degarelix or Triptorelin?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between Degarelix and Triptorelin?
Triptorelin offers a 6-month depot formulation reducing injection burden; degarelix requires monthly injection but eliminates the initial testosterone flare - convenience vs. flare avoidance tradeoff.
Evidence Comparison
Both: FDA/EMA approved for prostate cancer. Triptorelin (Trelstar): 6-month depot available, extensive European clinical data. Degarelix: monthly injection only, CS21 trial showing no testosterone flare. Comparable evidence quality; triptorelin has the dosing convenience advantage.
Evidence Context Favoring Degarelix
Flare-sensitive prostate cancer presentations requiring immediate testosterone suppression.
Evidence Context Favoring Triptorelin
Standard androgen deprivation where extended-release depot formulations and reduced injection frequency are preferred.
Side-by-Side Snapshot
| Evidence grade | Degarelix: Level A Triptorelin: Level A |
|---|---|
| Research status | Degarelix: FDA Approved Triptorelin: FDA Approved |
| Primary category | Degarelix: Sexual Health Triptorelin: Sexual Health |
| Cited studies | Degarelix: 3 Triptorelin: 3 |